Could Eosinopenia be a simple, fast and reliable biomarker in diagnosis of Covid-19?   
Yazarlar (2)
Doç. Dr. Muzaffer KATAR Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Dr. Öğr. Üyesi Osman DEMİR Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Makale Türü Özgün Makale
Makale Alt Türü Ulusal alan endekslerinde (TR Dizin, ULAKBİM) yayınlanan tam makale
Dergi Adı Cumhuriyet Medical Journal
Dergi ISSN 1305-0028
Dergi Tarandığı Indeksler TR DİZİN
Makale Dili İngilizce
Basım Tarihi 12-2020
Cilt No 42
Sayı 4
Sayfalar 422 / 433
DOI Numarası 10.7197/cmj.822996
Makale Linki http://dx.doi.org/10.7197/cmj.822996
Özet
Objective: Monitoring CBC subsets, particularly eosinophils. and inflammation markers, during admission and treatment of severe COVID-19 patients, can reveal key indicators of disease progression and stage to provide a basis for diagnosis and treatment for clinicians. Method: Our study is a retrospective case-control study. After taking aproval of Ministry of Health and Ethics Committee, the recorded clinical, laboratory and radiological data of 30 patients who were diagnosed with Covid-19, between 15 March and 15 June 2020, were compared with 30 healthy person by using appropriate statistical methods. Results: Both patients and conrols included 10 (33.3%) females and 20 (66.6%) males with a mean age of 57.2±15.46 and 60.07±20.59 respectively. Eosinophil counts of the patients on admission were significantly lower than the controls (p< 0.001). Eosinophil counts one week after admission were increased significantly compared to the admission levels (p= 0.004). Neutrophil/Eosinophil ratio, which is a reliable indicator of'Eosinopenia'in patients on admission was significantly higher than that of one week later (p= 0.041). EO1, NE1, NE2, PLT2/LYM2, LYM1/CRP1 and LYM2/CRP2 were the most predictive indexes. The AUCs of them were; 0.856, 0.778, 0.719, 0.738, 0.747 and 0.702 respectively, the cut-off values were; 0.04, 3.32, 3.21, 144, 59, 1.99 and 7.84 respectively, the sensitivity and specificity were 66.7% and 93.3% for EO1; 53.3% and 93.3% for NE1; 46.7% and 93.3% for NE2; and 80.1% and 80.5% for PLT2/LYM2; and 100% and 66.7% for LYM1/CRP1and 100% and 53.3% for LYM2/CRP2; respectively.Conclusions: Tracking …
Anahtar Kelimeler
BM Sürdürülebilir Kalkınma Amaçları
Atıf Sayıları
Google Scholar 3
Could Eosinopenia be a simple, fast and reliable biomarker in diagnosis of Covid-19?

Paylaş